In Brief This Week: PerkinElmer; Becton Dickinson; Sigma-Aldrich; Cepheid; Pathway Genomics; Accelrys; Pressure Biosciences; Cellular Dynamics | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment bank Mizuho Securities USA has upgraded its ratings on PerkinElmer and Becton Dickinson to Outperform from Neutral.

Analyst Peter Lawson raised PerkinElmer's rating and placed a $25 price target on its stock. He said the firm has less exposure to high-risk end markets, such as academic, pharma, and government, compared to its peers. He also said that business mix is more insulated from a cyclical downturn.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.